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ABSTRACT
Graft failure is associated with a high mortality rate. To date, regimens invoked for second transplants have
resulted in inconsistent engraftment with high transplant-related mortality (TRM). We here report 16
consecutive patients, aged 4-59 years, who received second HSCT (HSCT-2) at a median of 45 days following
primary or secondary failure of an initial unmodified (N  3) or T cell-depleted (TCD) (N  13) HSCT
(HSCT-1). HSCT-1 was administered after myeloablative total body irradiation (TBI)- or alkylator-based
conditioning for acute leukemias (N  7), MDS (N  6), CML (N  2), and Fanconi anemia (N  1). All
patients experienced 1 or more infectious complications between HSCT-1 and HSCT-2, and 10 patients had
active infections at the time of HSCT-2. Cytoreduction regimens used for HSCT-2 included fludarabine (Flu)
in combination with cyclophosphamide (CTX) (N  9), or thiotepa (Thio) (N  5). In addition, 1 patient
received Flu alone and 1 patient Thio combined with CTX. Antithymocyte globulin (ATG) (N  11) or
Alemtuzumab (N  3) was added pretransplant to prevent rejection. For HSCT-2, donors included
HLA-matched (N  3) or mismatched (N  8) related, or matched (N  2) or mismatched (N  3)
unrelated donors. The primary graft donor was used in 6 of 16 cases. The grafts administered were
unmodified peripheral blood stem cell transplantation (PBSCT) (N  5) or bone marrow transplantation
(BMT) (N  3), TCD PBSCT (N  8). All patients achieved engraftment at a median of 12 days and
evaluable patients achieved complete donor chimerism. Six patients are alive with a median follow-up of
49 months, including 4/9 conditioned with Flu/CTX. In this series, outcome was statistically superior for
younger patients (<20 years). In summary, second HSCT using the combination of a fludarabine- and
ATG-based, nonmyeloablative regimen and higher numbers of CD34 progenitor cells has been associ-
ated with acceptable toxicity and allowed consistent engraftment with hematopoietic reconstitution in
patients with previous graft failure.
© 2007 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Hematopoietic stem cell transplant (HSCT) is an
mportant therapeutic modality for the treatment of
ematologic and immunologic disorders. Graft failure
ollowing SCT is a rare but often fatal complication,
esulting in severe, prolonged pancytopenia and im- fune deﬁciency. Risk factors associated with graft
ailure include the type of donor, degree of HLA-
ismatch, cytoreduction regimen, and T cell-de-
leted (TCD) stem cell grafts [1,2]. Following graft
ailure, a second stem cell transplant represents the
est chance of long-term, disease-free survival (DFS)
or these patients. Achieving stable engraftment in
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J. H. Chewning et al.1314atients who undergo a second transplant following
raft failure is often difﬁcult with engraftment rates as
ow as 33% reported in the literature [3].
Fludarabine is a purine antimetabolite, which was
nitially used for the treatment of acute myelogenous
eukemia (AML) [4]. Over the last decade, based on
he profound immune suppression associated with ﬂu-
arabine, a number of cytoreductive regimens include
his drug to facilitate engraftment, especially in the
ontext of related HLA-mismatched transplants [5,6].
ludarabine has also been used for second stem cell
ransplants for patients with relapsed leukemia [7].
In this retrospective study, we describe 16 consec-
tive patients who received a second HSCT following
ailure of an initial HSCT. We were able to achieve
tem cell engraftment in all these high-risk patients
sing higher numbers of CD34 progenitor cells fol-
owing an immunoablative chemotherapy regimen
ith or without antithymocyte globulin (ATG).
ATIENTS AND METHODS
atient Characteristics
Sixteen consecutive patients who suffered graft
ailure following a ﬁrst HSCT (HSCT-1) per-
ormed between November 1997 and June 2005
ere evaluated. All 16 patients received a second
SCT (HSCT-2) at this institution. Two addi-
ional patients experienced graft failure during this
ime period and were evaluated for a second HSCT.
nfortunately, both these patients expired while
till being evaluated and prior to selection of donor
r cytoreductive regimen. During this same time
eriod, 673 allogeneic transplants were performed
t our institution with a cumulative incidence of
raft failure of 2.3%. The patient characteristics at
he time of ﬁrst transplant are summarized in Table
. There were 11 males and 5 females identiﬁed.
edian age of these patients at HSCT-1 was 22
ears (range: 4-59 years), with 8 patients 20 years
ld or younger. Patient diagnoses included acute
eukemias (N  7), myelodysplastic syndrome
MDS) (N  6), chronic myelogenous leukemia
CML) (N  2), and Fanconi anemia (N  1). At
he time of the ﬁrst transplant, 2 of the patients with
cute leukemia had relapsed disease. Informed con-
ent, including the discussion of the agents used for
ytoreduction and their respective side effects, as
ell as the overall risks of a second HSCT, was
btained prior to second transplant from all pa-
ients.
irst Transplants
Details of the ﬁrst SCT administered to each patient
nd the cytoreduction used in each case are described in
able 2. To facilitate analysis of the results of their 1econd transplants, the patients are grouped in this table
ccording to the preparative regimen and stem cell ma-
ipulation used for the second transplant (Table 3).
Of the 16 patients treated for graft failure, 3 had
eceived unmodiﬁed marrow (N  2) or cord blood
N  1) transplants from unrelated donors, whereas
3 patients had received TCD grafts from related
N  5) or unrelated (N  8) donors. The donors for
he 16 transplant patients were: HLA-matched related
N  3), HLA-matched unrelated (N  5), HLA-
ismatched related (N  2) and HLA-mismatched
nrelated (N 6). Donor unique allele disparities that
ould be recognized by residual host T cells (ie, HLA
ismatches predisposing to rejection) are speciﬁed in
able 2.
Conditioning for the ﬁrst transplants included my-
loablative doses of either total body irradiation (TBI) or
lkylating agents (busulfan  melphalan) in each case.
he regimens used were based on IRB-approved trans-
lant protocols targeting speciﬁc patient groups. Recip-
ents of unmodiﬁed marrow grafts (N  2) received
VHD prophylaxis consisting of cyclosporine or ta-
rolimus with short course methotrexate, whereas the
ord blood graft recipient received cyclosporine, ste-
oids, and ATG. Recipients of TCD grafts received
ither equine or rabbit ATG prior to transplant to pre-
ent rejection, but did not receive any additional drug
rophylaxis post transplant to prevent GVHD.
haracteristics of Graft Failures following
irst Transplants
Following the ﬁrst transplant, patients were mon-
tored with daily blood counts for evidence of engraft-
ent. Time of engraftment was recorded as the ﬁrst of
consecutive days in which neutrophil counts equaled
r exceeded 0.5  109/L. Primary graft failure was
eﬁned as a failure to recover neutrophil counts by
ay 25 posttransplant coupled with persistence of
arrow aplasia. Secondary graft failure was deﬁned as
raft failure occurring after initial partial or complete
ecovery of donor-type hematopoiesis, and was char-
cterized by recurrent pancytopenia with neutrophil
ounts 0.5  109/L, and marrow aplasia. Both pri-
ary and secondary graft failures were conﬁrmed in
ach case by cytogenetic and/or molecular demonstra-
ion of loss of donor-type blood elements. By these
eﬁnitions, 11 patients in this series had primary graft
ailure, and 5 suffered secondary graft failure.
In addition to prolonged pancytopenia, 10 patients
ith graft failure had 1 or more active issues entering
SCT-2. These included: CMV viremia/antigenemia
N  3), HHV-6 viremia (N  2), VRE bacteremia
N  1), Gram-negative sepsis/bacteremia (N  3),
oxoplasmosis (N  1), bacterial abscess (N  1),
neumonitis (N  1), pancreatitis (N  1), severe
nterocolitis (N  2), and hemorrhagic cystitis (N 
). The remaining 6 patients were stable at the time of
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Fludarabine-Based Regimen for Graft Failure 1315SCT-2, but had experienced the following compli-
ations in the interval following HSCT-1: bactere-
ia (N  3), CMV viremia/antigenemia (N  1),
neumonia (N  2), enterocolitis (N  1), and
eizures (N  1).
econd Transplants
The characteristics of the patients, donors, trans-
lants, and cytoreductive regimens used for the sec-
nd transplants in this series are summarized in Table
. Second transplants were received at a median time
f 45 days (range: 31-85 days) after ﬁrst transplant
HSCT2-HSCT1). The donors for the second trans-
lants were the same donors as for HSCT-1 in 6 cases,
f whom 4 were HLA-matched, and 2 were HLA-
ismatched, whereas a different donor was used in the
able 1. Patient and Transplant Characteristics
ge (years)
Median
Range
ex
Male
Female
iagnosis
Acute leukemia
Myelodysplastic syndrome
Fanconi anemia/aplastic anemia
Chronic myelogenous leukemia
irst transplant
Donor
Matched related
Mismatched related
Matched unrelated
Mismatched unrelated
tem cell manipulation
Unmodified
T cell depleted
econd transplant
Donor
Same as HSCT-1
Different
onor Matching
Matched related
Mismatched related
Matched unrelated
Mismatched unrelated
tem cell manipulation
Unmodified
T cell depleted
ytoreduction
Flu (30 mg/m2/day)  5 days
Flu (30 mg/m2/day)  5 days  Cy (60 mg/kg/day)  2 days
Flu (30 mg/m2/day)  5 days  Cy (60 mg/kg/day)  2 days
Flu (25 mg/m2/day)  5 days  Thio (5 mg/kg/day)  2 days
Flu (25 mg/m2/day)  5 days  Thio (5 mg/kg/day)  2 days
Cy (60 mg/kg/day)  2 days  Thio (5 mg/kg/day)  2 days
indicates number of patients; HSCT-1, ﬁrst hematopoietic
Cy, cyclophosphamide; Thio, thiotepa.ther 10 cases, of whom 1 was HLA-matched and 9 iLA-mismatched. For the 6 patients who received
econd grafts from the same related or unrelated do-
or who provided the ﬁrst transplant, the same donor
as selected because that donor was the only available
LA-matched sibling or unrelated donor, or because
he HLA disparity between that donor and the patient
as limited enough to permit the use of an unmodiﬁed
ematopoietic cell transplant. For the other 10 pa-
ients, a different donor was recruited. Seven patients
eceived TCD transplants from an HLA nonidentical
elated donor, either a parent (N  6) or a sibling
N  1, UPN 2478). Three patients received trans-
lants from a second unrelated donor (2 unmodiﬁed
nd 1 TCD) because their primary HLA-matched
nrelated donor was not readily available or willing to
rovide a second graft. For 5 of these 10 patients, we
N  16
22
4-59
11
5
7
6
1
2
3
2
5
6
3
13
6
10
3
8
2
3
8
8
Immunosuppression
ATG 1
— 2
ATG 7
ATG 3
Campath 2
Campath 1
ell transplant; ATG, antithymocyte globulin; Flu, ﬂudarabine;stem cntentionally selected a secondary donor whose HLA
Table 2. First Hematopoietic Stem Cell Transplant
UPN
Age
(Years)
Diagnosis-
Stage
Donor
Relation
HLA Mismatch
Rejection/GVHD
HLA Match
(R, GVHD)
Stem Cell
Source
Stem Cell
Manipulation TNC Dose
CD34*
Dose
(106/kg) Cytoreduction
Rejection/GVHD
Prophylaxis
Graft
Rejection
2402 4 MDS-RAEB Unrelated None 10/10, 10/10 BM Unmodified 4.93  108/kg ND Bu, Mel Tacrolimus 
MTX
Primary
2035 6 FA Unrelated A,C,DR,DQ/A,C,DR,
DQ
6/10, 6/10 Cord Blood NA 1.2  107/kg ND TBI, Cy* ATG-equine 
CSA
Primary
2963 6 AML Unrelated B,C/b 8/10, 9/10 BM T cell
Depleted
1.3  107/kg 0.8 TBI, Thio, Cy ATG-equine Primary
2050 8 AML-CR2 Related A,B,DR,DQ/A,B,DR,
DQ
6/10, 6/10 BM  PBSC T cell
Depleted
1.1  107/kg 5.4 TBI, Thio, Cy ATG-equine Primary
NA 8 AML-CR1 Unrelated None 10/10, 10/10 BM Unmodified 4.9  108/kg ND TBI, Cy CSA  MTX Primary
2180 11 ALL-CR3 Unrelated B,C,DQ/B,C,DQ 7/10, 7/10 BM T cell
Depleted
4.02  107/kg 2.8 TBI, Thio, Cy ATG-equine Primary
2478 24 ALL-relapse
(2nd)
Unrelated A/A 9/10, 9/10 BM T cell
Depleted
2.11  107/kg 1.1 Bu, Mel, Flu ATG-rabbit Primary
2397 54 MDS-RAEB-
IT (CR1)
Unrelated None 10/10, 10/10 BM T cell
Depleted
1.7  107/kg 1.0 TBI, Thio, Cy ATG-rabbit Primary
2194 41 CML-1st CP Related None 10/10, 10/10 BM T cell
Depleted
1.3  107/kg 1.3 TBI, Thio, Cy ATG-equine Secondary
2118 43 MDS-RA Related None 10/10, 10/10 PBSC T cell
Depleted
1.96  107/kg 16.1 TBI, Thio, Cy ATG-equine Secondary
2009 59 CML-1st CP Related None 10/10, 10/10 BM T cell
Depleted
2.62  107/kg 0.6 TBI, Thio, Cy ATG-equine Secondary
2320 20 ALL-relapse
(2nd)
Unrelated B,C,DQ/B,C 7/10, 8/10 BM T cell
Depleted
1.68  107/kg 1.6 Bu, Mel, Thio ATG-rabbit Primary
2697 26 ALL-CR2 Unrelated a/a 9/10, 9/10 PBSC T cell
Depleted
0.7  107/kg 6.8 TBI, Flu, Thio ATG-equine Secondary
2565 7 MDS-RAEB-
IT
Related A,C/A 8/10, 9/10 BM T cell
Depleted
4.76  107/kg 3.7 Bu, Mel, Flu ATG-rabbit Primary
2991 46 MDS-RA Unrelated None 10/10, 10/10 PBSC T cell
Depleted
0.6  107/kg 5.2 Bu, Mel, Flu ATG-equine Primary
2124 54 MDS-RA Unrelated None 10/10, 10/10 BM T cell
Depleted
2.5  107/kg 1.6 TBI, Thio, Cy ATG-equine Secondary
UPN indicates unique patient number; Age, patient age at time of ﬁrst stem cell transplant; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; FA, Fanconi’s anemia; AML,
acute myelogenous leukemia; CR, complete remission; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; HLA mismatch, mismatched HLA loci that are donor unique
disparities (rejection) or host unique disparities (GVHD)-upper case indicate HLA antigen differences whereas lower case indicates allelic differences; HLA match, number of matched loci for donor
and host—R indicates number of donor matched alleles and GVHD indicates the number of host matched alleles; BM, bone marrow; PBSC, peripheral blood stem cells; NA, not applicable; TNC,
total nucleated cell dose; ND, not determined or unavailable; Bu, busulfan; Mel, melphalan; TBI, total body irradiation; Cy, cyclophosphamide; Flu, ﬂudarabine; Thio, thiotepa; MTX, methotrexate;
ATG, anti-thymocyte globulin; CSA, cyclosporine A.
*TBI, Cy given at reduced dose (see text).
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Fludarabine-Based Regimen for Graft Failure 1317isparities differed from those of the original donor,
ased on our prior studies implicating host T cells
eactive against donor class I or II alleles as effectors of
arrow graft rejection [8,9].
For the second transplant, the preparative reg-
men was based on the cytoreduction regimen of the
rst transplant (HSCT-1) and on existing patient
oxicity following the ﬁrst transplant and prior to
he second transplant; for example, cyclophospha-
ide was not used in patients with cardiac toxicity.
he preparative conditioning consisted of ﬂudara-
ine (30 mg/m2/day  5 days) alone (N  1) or
equentially given with cyclophosphamide (60 mg/
g/day  2 days) (N  9), or ﬂudarabine (25 mg/
2/day  5 days) sequentially given with thiotepa (5
g/kg/day  2 days) (N  5). One patient was
repared with the same doses of thiotepa followed by
yclophosphamide. All but 2 of the patients were
reated with in vivo TCD prior to transplant to elim-
nate residual host T cells. The TCD agents employed
ncluded equine antithymocyte globulin (eATG) (N 
), rabbit antithymocyte globulin (rATG) (N  3), or
lemtuzumab (Campath) (N  3). eATG dosing range
as 30-120 mg/kg, and rATG was dosed at 5-12.5 mg/
g. The cytoreduction schema for the most common
reparative regimen (ﬂudarabine/cyclophosphamide/
TG) is shown in Figure 1. Posttransplant prophylaxis
gainst graft-versus-host disease (GVHD) was adminis-
ered to 13 of the 16 patients. Recipients of TCD second
ransplants received either no additional treatment (N
) or tacrolimus (N  5), beginning at a dose that was
djusted according to blood levels and maintained for 90
o 120 days posttransplant then tapered. Recipients of
nmodiﬁed second grafts received cyclosporine (CSP)
ith or without addition of mycophenolate mofetil
MMF) or steroids (N  6), methotrexate (MTX) alone
N  1), or steroids alone (N  1).
ransplants and Patient Evaluations
Bone marrow (BM) or peripheral blood stem cells
PBSC) were administered either unmodiﬁed or fol-
owing TCD. TCD of marrow was performed by
equential soybean lectin agglutination (SBA) fol-
owed by sheep erythrocyte rosetting (E-rosetting)
10]. PBSC transplants (PBSC) consisted of cells ob-
ained from the donors after mobilization with gran-
locyte-colony stimulating factor (G-CSF) and leuka-
heresis [11]. TCD of PBSC was performed by initial
ositive selection of CD34 cells on Isolex columns
ollowed by E-rosette depletion [12].
HLA class I and class II typing of all donor-
ecipient pairs was performed by sequence-speciﬁc
ligonucleotide probe (SSOP) analysis. Donor-recip-
ent match was determined by analysis of HLA-A, B,
, DRB, and DQB alleles. Degree of matching was
eported as the number of matched alleles of 10 pos- tible. Disparities unique to the donor, predisposing to
ejection, and to host, predisposing to GVHD, are
peciﬁed in Tables 2 and 3.
The presence and level of donor chimerism were
valuated in each patient by sequential cytogenetic
nd molecular analyses of peripheral blood and mar-
ow samples by ﬂuorescence in situ hybridization
FISH) in sex-mismatched donor-recipient pairs and
y quantitation of donor and recipient unique DNA
olymorphisms in sex-matched pairs.
GVHD was diagnosed and graded by the standard
riteria of Glucksberg et al. [13] as modiﬁed by Martin
t al. [14]. Acute GVHD (aGVHD) in this report
epresents the highest overall grade (I-IV) observed in
ach patient based on staging of the skin, liver, and
astrointestinal tract.
tatistical Analysis
A permutation test based on the log-rank statistic
as used to determine potential prognostic factors
hat would predict survival. The application of the
ermutation procedure resulted from the small num-
er of events in this data set. The primary endpoint
elected for analysis was survival. Because there were
o cases of graft failure following HSCT-2, analysis of
actors inﬂuencing engraftment was not possible.
nalyses of stem cell dose were based on the Wil-
oxon rank sum statistic.
ESULTS
ngraftment
Stem cell doses received for HSCT-1 and
SCT-2 are shown in Tables 2 and 3, respectively.
tem cell doses were signiﬁcantly higher in HSCT-2
ompared to HSCT-1 (P  .01).
Following HSCT-2, all of the 16 patients en-
rafted. The median time to engraftment for these
atients was 12 days (range: 9-21 days). There was no
orrelation between time to engraftment and (1) cy-
oreductive regimen, (2) stem cell manipulation, (3)
tem cell dose, or (4) stem cell donor (same or differ-
nt donor as HSCT-1). In this small cohort, there was
o statistical difference between neutrophil or platelet
ecovery time following TCD SCT, compared with
nmodiﬁed transplants.
VHD
Three patients developed aGVHD, 1 of which
eveloped manifestations of aGVHD beyond 100
ays posttransplant. Disease was limited to the skin
nd scored as grade I in 2 cases (UPN 2402 and
PN 2050). A third patient (UPN 2991) had com-
ined grade I skin and gut involvement, resulting in
rade II GVHD. Both patients with disease limited
o the skin had received TCD SCT, and patient
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J. H. Chewning et al.1318PN 2402 was also given additional tacrolimus
herapy as GVHD prophylaxis. Patient UPN 2991
eceived an unmodiﬁed SCT followed by GVHD
rophylaxis with cyclosporine (CSa) and MMF. All
patients had complete resolution of symptoms
ithout further complications.
Ten patients survived greater than 100 days, and
ere evaluable for chronic graft-versus-host disease
cGVHD). Of these patients, a single patient (UPN
194) developed extensive cGVHD with severe
anifestations involving the skin, gut, and liver.
he patient had received a TCD, related, identical
M-derived SCT (HSCT-1), followed by an un-
odiﬁed PBSCT from the same donor (HSCT-2)
ith CSA and MMF as GVHD prophylaxis. This
atient’s GVHD was refractory to therapy, and his
isease progressed to multiple-organ system in-
olvement. The patient ultimately died as a result of
omplications of cGVHD.
urvival
Six patients are alive at a median follow-up time
able 3. Second Hematopoietic Stem Cell Transplant
PN
Age
(years)
HSCT1–
HSCT2
(days)
Donor
HSCT-2
Donor
Relation
HLA m
Rejectio
2402 4 42 Different Related B,C,DR,
DR,DQ
2035 6 48 Different Related DR,DQ/
2963 6 36 Different Related b,DR,DQ
DQ
2050 8 33 Different Related a,B,C,DR
DR,DQ
0 8 37 Different Related A,B,DR/
2180 11 40 Different Related A,B,C/A
2478 24 35 Different Related A,B,C,D
B,C,D
2397 54 69 Different Unrelated dr/dr
2194 41 68 Same Related None
2118 43 70 Same Related None
2009 59 82 Same Related None
2320 20 42 Different Unrelated B,c,DQ/
2697 26 49 Same Unrelated a/a
2565 7 31 Same Related A,C/A
2991 46 63 Different Unrelated None
2124 54 85 Same Unrelated None
PN indicates unique patient number; Age, patient age at time of ﬁ
second BMT (in days); Different, stem cell donor for HSCT2 is
HLA mismatch, mismatched HLA loci which are donor uniqu
differences while lower case indicates allelic differences; HLA M
stem cell; BM, bone marrow; TNC, total nucleated cell dose; Flu
globulin; CSA, cyclosporine A; MMF, mycophenylate moﬁtil;
engraftment; ND, not determined; N/A, not applicable; EBV-
graft-versus-host disease.f 49 months (range: 10-97 months), resulting in an pverall survival (OS) rate of 35% at 3 years by
aplan-Meier analysis (95% conﬁdence interval:
10%-60%]) (Figure 2A). The DFS rate for this
ohort is 18% at 3 years (95% conﬁdence interval:
1%-41%]) from the development of leukemic re-
apse in 2 patients 6 and 30 months, respectively,
ollowing second SCT (UPN 2402 and 2565) (Fig-
re 2B). Both patients received a third SCT, and are
urrently in remission 50 and 10 months post
SCT-3.
The median survival time was 44 days for the
emaining 10 patients. Six patients died within 100
ays posttransplant. Causes of death were pneumonia
N  3), sepsis with multiorgan failure (N  2), and
ncephalopathy (N  1). Four patients died 6-15
onths posttransplant from GVHD (N  1), relapse
N  1), pneumonia (N  1), and Epstein-Barr virus
EBV) lymphoproliferative disorder (N  1). There
ere no patient deaths from acute organ failure re-
ated to the cytoreductive regimen.
In this small series, the long-term OS of patients
ged 20 years or younger was superior to that of older
-
D
HLA Match
(R, GVHD)
Stem
Cell
Source
Stem Cell
Manipulation TNC Dose
, 6/10, 6/10 PBSC T cell depletion 3.5  107/kg
8/10, 8/10 PBSC T cell depletion 1.2  107/kg
, 7/10, 7/10 PBSC T cell depletion 3.0  107/kg
, 6/10, 5/10 PBSC T cell depletion 0.9  107/kg
7/10, 7/10 PBSC T cell depletion 2.0  107/kg
7/10, 7/10 PBSC T cell depletion 0.3  107/kg
, 5/10, 5/10 PBSC T cell depletion 1.0  107/kg
9/10, 9/10 PBSC T cell depletion 0.4  107/kg
10/10, 10/10 PBSC Unmodified 10.3  108/kg
10/10, 10/10 BM Unmodified 3.0  108/kg
10/10, 10/10 PBSC Unmodified 8.5  108/kg
7/10, 8/10 BM Unmodified 2.9  108/kg
9/10, 9/10 PBSC Unmodified 6.1  108/kg
8/10, 9/10 PBSC Unmodified 26.0  108/kg
10/10 10/10 BM Unmodified 3.3  108/kg
10/10 10/10 PBSC Unmodified 5.7  108/kg
cell transplant; HSCT1–HSCT2 indicates time between ﬁrst and
nor for HSCT1; Same, donor the same for HSCT-1 and HSCT-2;
ction) or host unique (GVHD)-upper case indicate HLA antigen
umber of matched loci for donor and host; PBSC, peripheral blood
abine, Cy, cyclophosphamide; Thio, thiotepa; ATG, antithymocyte
methotrexate; PDN, prednisone; Engraft, posttransplant day of
bstein-Barr virus-associated lymphoproliferative disease; GVHD,ismatch
n/GVH
DQ/B,C
B,DQ
/b,DR
/a,B,C
A,B,DR
,B,C
R,dq/A
R,dq
B,c
rst stem
not do
e (reje
atch, n
, ﬂudar
MTX,
LPD, Eatients (P .02). Five of 8 younger patients are alive,
w
a
H
H
p
d
d
r
d
(
i
b
i
r
p
e
n
n
a
c
c
c
D
o
H
a
t
s
o
b
m
T
1
g
d
n
g
c
e
(
i
[
s
m
p
g
n
t
s
l
w
T
Fludarabine-Based Regimen for Graft Failure 1319hereas only 1 of the 8 patients older than 20 years of
ge survived over 6 months.
The outcome of patients receiving stem cells for
SCT-2 from a second donor different than that of
SCT-1 was more favorable than the outcome of
atients receiving a second SCT from the same
onor. Five of 10 patients with different stem cell
onors survived compared with only 1 of 6 patients
eceiving stem cells from the same donor. This
ifference, however, was not statistically signiﬁcant
P  .10). Similarly, the outcome of patients receiv-
ng TCD stem cells in HSCT-2 was somewhat
etter than the outcome of those receiving unmod-
ﬁed stem cells. Four of 8 patients survived after
eceiving TCD SCT compared with only 2 of 8
atients who received an unmodiﬁed SCT. How-
ver, this difference was also not found to be sig-
iﬁcant (P  .17). Patient 100-day mortality was
ot statistically different when analyzed for patient
ge, donor source (same versus different), or stem
ell manipulation. Similarly, stem cell source and
ytoreduction regimen were not found to be asso-
iated with differences in engraftment or survival.
ISCUSSION
HSCT is an important modality in the treatment
f high-risk hematologic and immunologic disorders.
able 3. (Continued)
CD34 Dose
Cyto
Reduction
Rejection
Prophylaxis
GVHD
Prophylaxis
34.0  106/kg Flu/Cy ATG-equine Tacrolimus
7.3  106/kg Flu/Cy ATG-rabbit Tacrolimus
30.0  106/kg Flu/Cy None-did not
tolerate
ATG-rabbit
None
5.2  106/kg Flu/Cy ATG-equine None
12.0  106/kg Flu/Cy ATG-equine Tacrolimus
2.8  106/kg Flu/Cy ATG-equine Tacrolimus
10.0  106/kg Flu/Thio Campath None
3.4  106/kg Flu/Thio ATG-equine Tacrolimus
ND Flu/Cy None CSAMMF
ND Flu/Cy ATG-equine MTX
13.0  106/kg Flu/Cy ATG-equine steroids
ND Flu/Thio ATG-equine CSAMMF
11.0  106/kg Flu/Thio Campath CSA
23.8  106/kg Thio/Cy Campath CSA
8.3  106/kg Flu/Thio ATG-rabbit CSAMMF
5.7  106/kg Fludarabine
alone
ATG-rabbit CSAPDNowever, HSCT has an increased risk of morbidity snd mortality because of complications such as organ
oxicity, infections, and GVHD. Graft failure repre-
ents another rare but potentially lethal complication
f HSCT.
The incidence of graft failure has been reported to
e as low as 0.1% for unmodiﬁed HSCT from HLA-
atched siblings administered after myeloablative,
BI-containing regimens for leukemia, and as high as
7% following TCD HSCT [1,15]. Risk factors for
raft failure reported in the literature include HLA
isparity [16-19], TCD [17,20], HSCT for nonmalig-
ant disorders, such as aplastic anemia [17] or hemo-
lobinopathies [21,22], donor age and sex [8], and
ytoreduction using chemotherapy only or nonmy-
loablative regimens [23,24]. Umbilical cord blood
UCB) transplants have also been associated with an
ncreased risk of graft failure, with rates of 10%-30%
25,26].
It is important to differentiate graft failure as-
ociated with allogeneic HSCT for malignant he-
atologic disorders where graft failure is an acute
rocess often associated with graft rejection, and
raft failure associated with allogeneic HSCT for
onmalignant hematologic disorders such as aplas-
ic anemia and hemoglobinopathies where it pre-
ents as a subacute process associated with pro-
onged mixed chimerism occurring over periods of
eeks to months. The patients described in our
t GVHD
(Grade) Chimerism
Survival
Time
(days) Cause of Death
Acute skin (I) 100% donor 1870 N/A
0 100% donor 2900 N/A
0 100% donor 400 N/A
Acute skin (I) 100% donor 202 Infection
0 100% donor 2700 N/A
0 100% donor 177 EBV-LPD
0 100% donor 178 Relapse
0 100% donor 41 Encephalopathy
Chronic-skin,
gut, liver
(extensive)
100% donor 461 GVHD
0 ND 37 Infection
0 ND 26 Infection
0 100% donor 47 Infection
0 ND 27 Infection
0 100% donor 1430 N/A
Acute-skin
and GI (II)
100% donor 300 N/A
0 100% donor 35 InfectionEngraf
(days)
14
13
13
12
10
12
10
12
11
21
9
19
12
11
14
14eries belong to the ﬁrst patient group. A review of
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J. H. Chewning et al.1320he literature revealed 6 retrospective descriptions
f such patients [3,8,19,27-29].
The treatment of patients with graft failure fol-
owing HSCT has included the reinfusion of autolo-
ous cryopreserved progenitor cells [30] or high-dose
ematopoietic growth factors [31], both of which have
een associated with a poor outcome for those pa-
ients with true graft failure. Second HSCT repre-
ents the therapeutic option with the best chance for
ong-term survival for patients with primary or sec-
ndary graft failure. In this setting, stem cells from the
ame or a different donor are infused to the patient
ither with or without additional cytoreduction. In the
reviously cited series, OS and DFS rates have varied
rom 6% to 43% [3,8,19,27-29].
There are few studies analyzing engraftment or
urvival outcomes based on donor choice for second
SCT. Following failure of an HLA-matched graft,
he same donor is most commonly recruited because a
imilarly matched secondary donor is rarely available.
n addition, because of the tenuous condition of these
atients, the time required to identify and recruit a
econd donor limits this option. Nevertheless, in a
eries by Grandage et al. [19], 12 pediatric patients
18 years) suffered graft failure a median of 5
onths following HSCT from an unrelated donor.
econd unmodiﬁed HSCT using a different unrelated
onor was attempted in 7 patients. Donor source did
ot affect outcome in this study, with 3 of 6 patients
urviving after receiving a second HSCT from the
ame donor compared to 2 of 6 surviving recipients of
econd HSCT from a different donor. Overall, 6 of 9
atients achieved engraftment and 5 were long-term
urvivors. However, there was an increased risk of
GVHD, with 67% grade II-IV GVHD [19]. In our
imited series recipients of second HSCT from a dif-
erent donor tended to have a better outcome (5 of 10
ong-term survivors) than those who received HSCT
FLU FLU FLU FLU FL
             30 mg/m2/day x 5 
CY CY
           60 mg/Kg/da
          Rabbit ATG  2.5 mg/Kg/day 
ATATGATGATG
Day  -6 -5 -4 -3 -
igure 1. Schema for the most frequently administered cytoreductio
hown above the corresponding days these agents were administer
SCT-2 box indicates the administration of the second stem cell grom the same donor (1 of 6 long-term survivors), rlthough this was not statistically signiﬁcant (P .11).
trikingly, in our series using TCD second trans-
lants, the incidence of grade II-IV aGVHD or ex-
ensive cGVHD was low.
The sole purpose of a cytoreductive regimen in
he setting of second HSCT is immunoablation in
rder to secure stem cell engraftment. There is usually
o further need for antileukemic or myeloablative
ffects, as patients are pancytopenic with aplastic mar-
ow. Engraftment rates following second HSCT have
aried widely in the literature, reﬂecting the hetero-
eneity of the reported patient populations [3,27].
ne of the ﬁrst reported studies using a second
SCT was performed by Kernan et al. [8] at this
nstitution in patients with graft failure following a
CD HSCT. Four initial patients received a second
SCT from the same donor without immune sup-
ression, and all 4 experienced a second rejection.
ubsequently, 5 patients received another dose of do-
or stem cells after pretreatment with ATG and ste-
oids with 3 of 5 engrafting and 1 long-term survivor.
n a study by Guardiola et al. [27], 82 patients received
second SCT following primary or secondary graft
ailure of a ﬁrst HSCT administered for acute or
hronic leukemia and aplastic anemia. Of these 82
atients, 51 achieved engraftment, with a 73% overall
robability of engraftment. Engraftment occurred at a
ean of 17 days following HSCT. No study has spe-
iﬁcally addressed the use of ﬂudarabine-containing
egimens for the stable engraftment of donor stem
ells following a second SCT after graft failure. We
chieved engraftment in all patients in this series using
udarabine-based chemotherapy regimens, with or
ithout ATG, at a median of 12 days after stem cell
nfusion.
Several centers have favored G-CSF-mobilized
BSCs over bone marrow-derived stem cells because
he former yields increased numbers of stem cells. A
HSCT-2
   -1  0 
en. Chemotherapeutic agents and ATG are displayed as a box and
U indicates ﬂudarabine and CY indicates cyclophosphamide. The
d is shown above the day of transplant (day 0).U
y x 2 
x 4 
G
2 
n regim
ed. FLeport by Zecca et al. [32] showed engraftment of 2
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Fludarabine-Based Regimen for Graft Failure 1321atients following graft failure using PBSCs. The only
arger study to address PBSC versus bone marrow
tem cells reported higher engraftment rates but
quivalent OS following PBSC transplants adminis-
ered for graft failure. The authors of this study did
ot report stem cell numbers for PBSCT and BM
27]. In our series, increased stem cell numbers were
sed for HSCT-2 to improve engraftment rates. The
ose of CD34 cells was statistically higher in
SCT-2 compared to HSCT-1 (P  .01). The use of
ncreased CD34 stem cell numbers in HSCT-2
ikely contributed to the high engraftment rate in this
atient population. The use of megadose CD34 has
lso been associated with low graft failure rates and
ow GVHD incidence, even in the setting of HLA-
ismatch [33]. There is no literature on the use of
igure 2. Kaplan-Meier probability of overall (A) and disease-free
B) survival by age following second HSCT.egadose stem cells in the setting of graft failure. All matients in this study engrafted, and no statistical dif-
erence was seen in disease-free or overall survival
ccording to stem cell source.
The use of TCD stem cells for second transplant
ollowing graft failure has not been well studied. Most
f the literature includes only unmodiﬁed transplants
or these patients. The largest series of patients in-
luded 12% who received TCD second grafts follow-
ng primary graft failure, but no separate analysis of
hese patients was performed [27]. In our study, 8 of
6 patients received TCD PBSCs. Four of these pa-
ients are alive versus only 2 of 8 patients receiving
onventional BM or PBSC, although this result was
ot statistically signiﬁcant (P  .13). Fifteen patients
urvived greater than 30 days and 10 survived 100
ays posttransplant, resulting in a 25% overall inci-
ence of aGVHD (grade I or II) and a 10% incidence
f cGVHD.
The patients in this study received a second
SCT following primary graft failure at a median
nterval time (HSCT2-HSCT1) of 45 days, with all
atients transplanted within 3 months of HSCT-1.
he patients in this series therefore represent a high-
isk population based on the short interval time be-
ween the ﬁrst and second transplant. Previous studies
ave shown an increased interval between SCT is
ssociated with improved patient survival [19,27]. Spe-
iﬁcally, patients receiving HSCT-2 80 days follow-
ng primary graft failure were shown to have a lower
00 day transplant-related mortality and increased
-year survival [27].
Infectious etiologies were the principal cause of
ortality in 6 patients in this series. Other causes of
eath included encephalopathy, relapse, GVHD, and
BV lymphoma. Mortality was highest in the peri-
ransplant time period, with 6 patients dying within
00 days of transplant. As previously described, these
atients represented a high-risk population. Thirteen
atients in this study had infectious complications
ollowing HSCT-1, and 10 of these patients had active
nfectious issues entering HSCT-2. It is possible that
mmunosuppression secondary to ﬂudarabine resulted
n the increased mortality in this at-risk population.
ther factors, however, such as immunosuppression
rom the previous transplant (HSCT-1), prolonged
ancytopenia from graft failure, and the high fre-
uency of preceding and ongoing infections at
SCT-2 may also have contributed to the mortality
rom infectious etiologies. Ongoing progress in the
anagement of peritransplant complications, such as
doptive T cell therapy for EBV and cytomegalovirus
CMV) and improved immunomodulators for GVHD
reatment, will continue to improve survival of these
atients following stem cell engraftment of second
rafts.
We have shown that achieving stem cell engraft-
ent with a second HSCT is possible following an
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J. H. Chewning et al.1322nitial graft failure by using an immunosuppressive,
inimally toxic secondary cytoreduction, and in-
reased stem cell numbers. In this study, we were able
o obtain stem cell engraftment in all of these high-
isk patients. Fewer patients received a TCDHSCT-2
ompared to HSCT-1, and it is possible that this
ontributed to less graft failure in this cohort. Never-
heless, all 8 recipients of TCD transplants engrafted.
ytoreduction was relatively well tolerated with no
cute organ failure from toxicity, including no cases of
eno-occlusive disease or grade III-IV mucositis. We
eport an OS rate of 37%, with a median follow-up of
9 months. Younger patients (20 years) had a supe-
ior survival rate (5 of 8 surviving) than those older
han 20 years (1 of 8 patients surviving) (P  .01). In
ddition, there was a trend toward better outcome for
ecipients of TCD HSCT and transplants from dif-
erent donors. We have found that a ﬂudarabine-
ased regimen including thiotepa or cyclophospha-
ide along with ATG, followed by a TCD PBSC
ransplant containing higher numbers of progenitor
ells from a different donor resulted in consistent
ngraftment. In these patients, there is a need for
articular attention to infectious risk during the peri-
ransplant and early posttransplant periods. A pro-
pective multicenter study that would include larger
atient numbers, using a ﬂudarabine-containing cy-
oreductive regimen followed by TCD PBSCT with
ggressive posttransplant infectious prophylaxis for
atients with graft failure could be beneﬁcial in study-
ng this promising approach to graft failure posttrans-
lant.
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